In a phase II study, SI-B001 demonstrated anti-tumor activity with manageable toxicity when combined with chemotherapy in locally advanced or metastatic EGFR/ALK wild-type NSCLC in the second-line setting [116]. Here, EGFR is linked to neoplasm.